Changes were evaluated over 10 years in the in vitro resistance of human periodontopathic strains of Parvimonas micra to four antibiotics. Subgingival biofilms culture positive for P. micra from 300 United States adults with severe periodontitis in 2006, and from a similar group of 300 patients in 2016, were plated onto anaerobically incubated enriched Brucella blood agar alone, or supplemented with either doxycycline (4 mg/L), clindamycin (4 mg/L), amoxicillin (8 mg/L), or metronidazole (16 mg/L). P. micra growth on antibiotic-supplemented media indicated in vitro resistance to the evaluated antibiotic concentration. P. micra resistance was significantly more frequent among patients in 2016, as compared to 2006, for doxycycline (11.3% vs. 0.3% patients; 37.7-fold increase), and clindamycin (47.3% vs. 2.0% patients; 23.7-fold increase) (both p < 0.001), whereas resistance to amoxicillin (2.3% vs. 1.0% patients) and metronidazole (0% vs. 0.3% patients) remained low and statistically unchanged between the two patient groups (p-values > 0.05). No P. micra isolates in 2006 or 2016 were jointly resistant in vitro to both amoxicillin and metronidazole. The alarming increases in subgingival P. micra resistance to doxycycline and clindamycin raise serious questions about the empiric use of these antibiotics, either locally or systemically, in the treatment of United States periodontitis patients harboring subgingival P. micra.

中文翻译：

---

人类牙周病原体Parvimonas micra对抗生素的耐药性超过10年

在过去的十年中，评估了人类牙周病微支圆盘菌对四种抗生素的体外抗药性变化。将2006年来自300名美国严重牙周炎的成年人和2016年来自300名患者的类似组的龈下生物膜培养阳性，涂在单独厌氧孵育富集的布鲁氏菌血琼脂上，或补充强力霉素（4 mg / L），克林霉素（4 mg / L），阿莫西林（8 mg / L）或甲硝唑（16 mg / L）。在补充了抗生素的培养基上P. micra的生长表明体外对评估的抗生素浓度有抗性。对虾与2006年相比，2016年多西环素（11.3％比0.3％的患者; 37.7倍增加）和克林霉素（47.3％比2.0％的患者; 23.7倍的增加）患者的耐药性明显高于2006年p <0.001），而对阿莫西林（2.3％比1.0％的患者）和甲硝唑（0％对0.3％的患者）的抵抗力仍然很低，并且在两个患者组之间统计上没有变化（p值> 0.05）。在2006年或2016年，没有任何P. micra分离株对阿莫西林和甲硝唑具有共同的体外抗药性。龈下P. micra的惊人增加对多西环素和克林霉素的抗药性引起了关于在局部或全身使用这些抗生素来治疗美国牙周炎患者的牙龈下脓肿的局部使用或全身使用的严重疑问。